AXNX | Axonics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	70.98 - 70.98
52 Week Range	55.09 - 71.05
Beta	0.89
Implied Volatility	34.15%
IV Rank	0.41%
Day's Volume	N/A
Average Volume	474,464
Shares Outstanding	51,109,200
Market Cap	3,627,731,016
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2018-10-31

Valuation
Profitability
Growth
Health
P/E Ratio	-709.80
Forward P/E Ratio	-125.75
EPS	-0.10
1YR Price Target	75.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	797
Country	USA
Website	AXNX

Axonics Inc is a United stated based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinence.

AXNX's peers: BFLY, CYRX, NARI, NNOX

*Chart delayed

Analyzing fundamentals for AXNX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see AXNX Fundamentals page.

Watching at AXNX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on AXNX Technicals page.